Mylan latest caught up in DOJ probe of generic drug prices

Eric Palmer Mylan said today that it got a special delivery from the Justice Department Thursday, making it the most recent of a string of drugmakers to get a subpoena from federal ...

Look out, Teva–Novartis’ Copaxone generic is off to a speedy start

Carly Helfand The launch for Glatopa, the new generic of Teva's Copaxone from Novartis' Sandoz, is still in the very early going. But so far, things look good–very good. FiercePharma ...

Does brand + generic really add up? Sandoz, Actavis execs count the ways

Carly Helfand These days, companies are increasingly looking to put both branded and generic meds under one roof. And Peter Goldschmidt, the U.S. president of Novartis' Sandoz unit, ...

Consumer group petitions FDA to pull generic antifungal med

Carly Helfand Currently, there are several generics on the U.S. market of oral antifungal agent ketoconazole. But consumer advocacy organization Public Citizen is trying to change that. FiercePharma ...

Pfizer grabs Hospira’s biosims, generic injectables in $15B takeover

Tracy Staton Pfizer has snapped up Hospira, an injectables specialist, for $ 90 per share, or some $ 15 billion, plus debt assumption. FiercePharma News

UCB joins pharma’s slimdown craze, unloads U.S. generic drug business for $1.53B

Emily Wasserman Amid the pharma's slimdown craze, Belgium's UCB is getting in on the action by selling its U.S. generic drug unit for $ 1.53 billion. FiercePharma News

FDA lets Endo, Dr. Reddy’s make Valcyte copies but stays mum on status of Nexium generic

Eric Palmer The FDA says it has approved two companies to make generics of Roche's Valcyte but will not give any clarity on plans for a generic of AstraZeneca's blockbuster ...

FDA yanks Ranbaxy’s tentative approval for generic Nexium

Eric Palmer At about the same time that AstraZeneca CEO Pascal Soriot was telling investors its earnings had been boosted because no generic of blockbuster Nexium had appeared, Ranbaxy ...

Insurers balk at pricey generic version of ancient GSK heart drug

Arlene Weintraub The heart drug digoxin–a generic version of GlaxoSmithKline's Lanoxin–used to cost just pennies a pill, making it a prescription that insurance companies ...

UPDATE: Ranbaxy’s generic of Novartis blockbuster Diovan approved for launch

Eric Palmer The long-delayed and highly anticipated launch of generic Diovan is on the way, which is a bummer for Novartis and a huge boost for Indian drugmaker Ranbaxy Laboratories. ...

Actavis slaps struggling Vivus with generic threat

Carly Helfand After a botched launch for obesity drug Qsymia, a bitter proxy war, a mass exodus of its directors and management and a continued sales struggle, the last thing Vivus ...

GSK touts Anoro results as it preps for generic attacks on $8B-seller Advair

Carly Helfand With aging top dog Advair losing ground to generic and branded competitors alike, GlaxoSmithKline is grooming a lineup of respiratory up-and-comers to step in with their ...
Page 1 of 41234
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS